Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too

This article was originally published in The Pink Sheet Daily

Executive Summary

Compound helps bowel function in dying patients on opioids.
Advertisement

Related Content

Relistor Expansion Plans In Question Following “Complete Response” Letter
Relistor Expansion Plans In Question Following “Complete Response” Letter
Exit Stage Left: As Pfizer Merger Nears, Wyeth Ends its Partnership with Progenics
Nektar Starts Major Push In Opioid-Induced Constipation Space
First Roche, Then Bristol: Who’s Next?
Wyeth/Progenics’ Relistor Fails Second Phase III POI Study
Adolor/GSK’s Entereg Approved By FDA
Entereg User Fee Date Pushed Back To May
FDA Extends Wyeth, Progenics NDA Review For Methylnaltrexone Until April
FDA Extends Wyeth, Progenics NDA Review For Methylnaltrexone Until April

Topics

Advertisement
UsernamePublicRestriction

Register

PS067656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel